AR063923A1 - Sales del acido zoledronico, procesos de preparacion y composiciones - Google Patents
Sales del acido zoledronico, procesos de preparacion y composicionesInfo
- Publication number
- AR063923A1 AR063923A1 ARP070105215A ARP070105215A AR063923A1 AR 063923 A1 AR063923 A1 AR 063923A1 AR P070105215 A ARP070105215 A AR P070105215A AR P070105215 A ARP070105215 A AR P070105215A AR 063923 A1 AR063923 A1 AR 063923A1
- Authority
- AR
- Argentina
- Prior art keywords
- zoledronic acid
- salts
- compositions
- monohydrate
- crystalline form
- Prior art date
Links
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical class OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 title abstract 6
- 229960004276 zoledronic acid Drugs 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- 150000004682 monohydrates Chemical class 0.000 abstract 4
- 241001465754 Metazoa Species 0.000 abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se refiere a formas cristalinas de sales de ácido zoledrónico de baja solubilidad en agua, al proceso para la preparación de estas formas cristalinas, a composiciones que contienen estas formas cristalinas, y al uso de estas formas cristalinas en métodos de diagnóstico o en el tratamiento terapéutico de animales de sangre caliente, en especial seres humanos. La presente se refiere a la forma cristalina del monohidrato de ácido libre del ácido zoledrónico, al proceso para la preparación de la forma cristalina del monohidrato de ácido libre del ácido zoledrónico, a composiciones que contienen la forma cristalina del monohidrato de ácido libre del ácido zoledrónico, y al uso de la forma cristalina del monohidrato de ácido libre del ácido zoledrónico en métodos de diagnóstico o en el tratamiento terapéutico de animales de sangre caliente, en especial seres humanos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06124850A EP1925621A1 (en) | 2006-11-27 | 2006-11-27 | Crystalline forms of zoledronic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063923A1 true AR063923A1 (es) | 2009-02-25 |
Family
ID=37909616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105215A AR063923A1 (es) | 2006-11-27 | 2007-11-23 | Sales del acido zoledronico, procesos de preparacion y composiciones |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100056481A1 (es) |
| EP (2) | EP1925621A1 (es) |
| JP (1) | JP2010510970A (es) |
| KR (1) | KR20090083407A (es) |
| CN (1) | CN101535323A (es) |
| AR (1) | AR063923A1 (es) |
| AU (1) | AU2007324833A1 (es) |
| BR (1) | BRPI0719567A2 (es) |
| CA (1) | CA2670638A1 (es) |
| CL (1) | CL2007003389A1 (es) |
| MX (1) | MX2009005413A (es) |
| PE (1) | PE20081391A1 (es) |
| RU (1) | RU2009123936A (es) |
| TW (1) | TW200829598A (es) |
| WO (1) | WO2008064849A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2407746C2 (ru) * | 2008-09-29 | 2010-12-27 | ЗАО "Фарм-Синтез" | Радиофармацевтическое средство для диагностики и лечения (терапии) костных поражений скелета и способ его получения |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| PT2459176T (pt) | 2009-07-31 | 2017-12-11 | Gruenenthal Gmbh | Método de cristalização e biodisponibilidade |
| WO2011014781A1 (en) | 2009-07-31 | 2011-02-03 | Thar Pharmaceuticals, Inc. | Novel oral forms of a phosphonic acid derivative |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| HUE025737T2 (en) * | 2009-09-01 | 2016-05-30 | Univ Duke | Bisphosphonate compositions and methods for treating heart failure |
| WO2011128424A1 (en) | 2010-04-16 | 2011-10-20 | Novartis Ag | Methods and compositions for improving implant osseointegration |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| JP6492321B2 (ja) * | 2015-03-23 | 2019-04-03 | 株式会社大阪合成有機化学研究所 | ［１−ヒドロキシ−２−（イミダゾ［１，２−ａ］ピリジン−３−イル）エチリデン］ビスホスホン酸一水和物の製造方法 |
| EP3455229B1 (en) | 2016-05-13 | 2021-03-24 | Thar Pharma LLC | Novel crystalline forms |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| CN106749405B (zh) * | 2016-12-29 | 2019-07-16 | 江苏省原子医学研究所 | 一种咪唑杂环类双膦酸化合物及其制备方法、应用 |
| AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
| CN110551152A (zh) * | 2018-05-31 | 2019-12-10 | 四川科伦药物研究院有限公司 | 唑来膦酸一水合物及无水物晶型制备方法 |
| US20220193231A1 (en) * | 2019-04-11 | 2022-06-23 | Xiamen Innovax Biotech Co., Ltd. | Preparation of zinc zoledronate micro-nanoparticle adjuvant and use thereof as vaccine adjuvant |
| CN114728875A (zh) | 2019-12-13 | 2022-07-08 | 因思博纳公司 | 金属盐及其用途 |
| CN112778365A (zh) * | 2020-12-30 | 2021-05-11 | 华南理工大学 | 一种唑来膦酸钙配合物及其制备方法 |
| CN112724174A (zh) * | 2020-12-30 | 2021-04-30 | 华南理工大学 | 一种薄片状双膦酸钙配合物及其制备方法 |
| CN112646193A (zh) * | 2020-12-30 | 2021-04-13 | 华南理工大学 | 一种块状双膦酸钙配合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4244422A1 (de) * | 1992-12-29 | 1994-06-30 | Boehringer Mannheim Gmbh | Schwerlösliche Zink- und Magnesiumsalze von 1,1-Bisphosphonsäuren, ihre Herstellung und Verwendung als Arzneimittel |
| US20040097468A1 (en) * | 2002-11-20 | 2004-05-20 | Wimalawansa Sunil J. | Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment |
| EP1612212A1 (en) * | 2003-07-03 | 2006-01-04 | Teva Pharmaceutical Industries Ltd | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
| US20060178439A1 (en) * | 2005-01-04 | 2006-08-10 | Mohakhud Pradeep K | Crystalline form of zoledronic acid |
| AR054673A1 (es) * | 2005-07-28 | 2007-07-11 | Gador Sa | Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende |
| EP1931326A4 (en) * | 2005-09-12 | 2009-12-16 | Reddys Lab Ltd Dr | CRYSTALLINE TRIHYDRATE OF ZOLEDONIC ACID |
| WO2007125521A2 (en) * | 2006-05-02 | 2007-11-08 | Ranbaxy Laboratories Limited | Polymorphic form of zoledronic acid and processes for their preparation |
-
2006
- 2006-11-27 EP EP06124850A patent/EP1925621A1/en not_active Ceased
-
2007
- 2007-11-23 AR ARP070105215A patent/AR063923A1/es unknown
- 2007-11-23 PE PE2007001630A patent/PE20081391A1/es not_active Application Discontinuation
- 2007-11-26 WO PCT/EP2007/010255 patent/WO2008064849A1/en active Application Filing
- 2007-11-26 CL CL200703389A patent/CL2007003389A1/es unknown
- 2007-11-26 CA CA002670638A patent/CA2670638A1/en not_active Abandoned
- 2007-11-26 RU RU2009123936/04A patent/RU2009123936A/ru not_active Application Discontinuation
- 2007-11-26 KR KR1020097010727A patent/KR20090083407A/ko not_active Application Discontinuation
- 2007-11-26 US US12/515,742 patent/US20100056481A1/en not_active Abandoned
- 2007-11-26 TW TW096144824A patent/TW200829598A/zh unknown
- 2007-11-26 MX MX2009005413A patent/MX2009005413A/es not_active Application Discontinuation
- 2007-11-26 CN CNA2007800419850A patent/CN101535323A/zh active Pending
- 2007-11-26 AU AU2007324833A patent/AU2007324833A1/en not_active Abandoned
- 2007-11-26 EP EP07846821A patent/EP2089404A1/en not_active Withdrawn
- 2007-11-26 JP JP2009537559A patent/JP2010510970A/ja active Pending
- 2007-11-26 BR BRPI0719567-2A patent/BRPI0719567A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20081391A1 (es) | 2008-11-14 |
| CN101535323A (zh) | 2009-09-16 |
| BRPI0719567A2 (pt) | 2013-12-10 |
| MX2009005413A (es) | 2009-06-01 |
| EP2089404A1 (en) | 2009-08-19 |
| CA2670638A1 (en) | 2008-06-05 |
| JP2010510970A (ja) | 2010-04-08 |
| TW200829598A (en) | 2008-07-16 |
| CL2007003389A1 (es) | 2008-06-27 |
| RU2009123936A (ru) | 2011-01-10 |
| KR20090083407A (ko) | 2009-08-03 |
| AU2007324833A1 (en) | 2008-06-05 |
| US20100056481A1 (en) | 2010-03-04 |
| WO2008064849A1 (en) | 2008-06-05 |
| EP1925621A1 (en) | 2008-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063923A1 (es) | Sales del acido zoledronico, procesos de preparacion y composiciones | |
| PE20120083A1 (es) | Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a | |
| DOP2016000250A (es) | Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa | |
| AR052322A1 (es) | Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica | |
| CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
| NI201800051A (es) | Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer | |
| GT201200181A (es) | Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il}-fenil-amino]-pirimidin-4-il]-1-metil-urea y sales de las mismas | |
| GT200500360A (es) | Compuestos organicos | |
| UY32691A (es) | Compuestos de 1h-imidazo-[4,5-c]-quinolinona | |
| DE602006015963D1 (de) | Immunstimulatorisches verfahren | |
| BRPI0607330A2 (pt) | composto, processo para preparar o mesmo, composição farmacêutica, método para tratar inflamação ou prevenir apoptose em um indivìduo, e, uso do composto | |
| CL2011002130A1 (es) | Uso de una composicion que comprende una mezcla fisica o combinacion de polvos, granulos, cristales o agregados de sales de calcio, magnecio y hierro para el tratamiento de enfermedades relacionadas con la absorcion alterada de fosforo en seres humanos y animales. | |
| AR079050A1 (es) | Compuestos benzoimidazolicos y sus usos | |
| CL2013000866A1 (es) | Sales cristalinas oxalato y fosfato del conjugado naloxolpolietilenglicol; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento del dolor. | |
| UY33040A (es) | Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
| CO6382113A2 (es) | Compuestos quimicos | |
| AR075097A1 (es) | Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia | |
| GT200600421A (es) | Formas cristalinas polimórficas de la sal de di-sodio del ácido n-(5-clorosaliciloil)-8-aminocaprilico | |
| AR106331A2 (es) | N-benzoil-estaurosporina, forma ii | |
| AR053145A1 (es) | Sales de fosfato del compuesto 6-dimetilaminometil-1 (3-metoxifenil)-1,3-hidroxi-ciclohexano | |
| UY30798A1 (es) | Sales de timo depresores farmacéuticamente aceptables y procesos para su manufactura | |
| GT200500032A (es) | Piperazinas derivadas de urea para el tratamiento de la endometrosis | |
| AR085736A1 (es) | Compuestos de complejos de fe(iii) para el tratamiento y profilaxis de sintomas de deficiencia de hierro y anemias por deficiencia de hierro | |
| CL2014000489A1 (es) | Forma de cristal anhidra de rilapladib, forma 3; composicion farmaceutica que lo comprende; combinacion farmaceutica; su uso en el tratamiento de la enfermedad de alzheimer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |